关键数据
23.840今开
24.990最高
636.27K成交量
21.70市盈率 TTM
12.39市盈率动
--股息TTM
0.79%换手率
24.000昨收
22.501最低
15.37M成交额
80.58市盈率静
1.36市净率
0.00%股息率 TTM
6.40%ROA
60.91052周最高
0.16量比
24.14M净利润
80.39M总股本
1.1150每股收益TTM
1.98Beta
6.93%ROE
21.91052周最低
32.83%振幅
71.49%毛利率
1.94B总市值
-9.91回报/风险
5.09%风险率

即将为您带来更多新闻,敬请期待。。。
Veracyte Inc评分
-0.32与上次评分对比预测8.83
财务诊断8.11
技术分析6.13
公司估值6.85
机构认同度10.00
风险评估2.25
分析师评级
买入评级
58.545目标均价
+17.07%涨幅空间
Veracyte Inc 最新财报电话会记录
Veracyte (VCYT) 2026年第三季度业绩电话会:Decipher展望重置,2027年增长放缓
Veracyte 2026年第三季度营收增长15%至1.518亿美元,但公司重新调整了 Decipher 的增长预期,并预计2027年营收将实现中个位数增长。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Veracyte Inc 简介
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
行业生物技术与医疗研究
公司代码VCYT
员工数量824
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 14.43% |
|---|
| Artisan Partners Limited Partnership | 6.89% |
|---|
| State Street Investment Management (US) | 6.32% |
|---|
| Fidelity Management & Research Company LLC | 6.12% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 64.19% |
|---|
| Investment Advisor/Hedge Fund | 34.77% |
|---|
| Hedge Fund | 5.42% |
|---|
| Research Firm | 3.29% |
|---|
常见问题
Veracyte Inc(VCYT)的当前股价是多少?
Veracyte Inc(VCYT)的当前股价是 24.16。
Veracyte Inc股票的52周最高点是多少?
Veracyte Inc股票的52周最高点是60.91。
Veracyte Inc股票的52周最低点是多少?
Veracyte Inc股票的52周最低点是21.91。
现在Veracyte Inc(VCYT)的股票是买入、持有还是卖出?
根据分析师评级,Veracyte Inc(VCYT)的总体评级为买入,目标价格为58.55。
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是1.11。